Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
ConclusionIn contrast to sevelamer, nicotinamide did not reduce circulating levels of low-molecular-weight uremic toxins other than phosphate, and neither agent reduced circulating uremic toxins of high-molecular-weight or protein-bound toxins. Sevelamer, but not nicotinamide, reduced serum endotoxin levels. Despite no change in serum C-reactive protein, the endotoxin-lowering effect of sevelamer may help to attenuate the inflammatory status of patients with chronic kidney disease.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Acetic Acid | Biochemistry | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Dialysis | Drugs & Pharmacology | Endocrinology | Heart | Hemodialysis | Hormones | Trimethylamine | Urology & Nephrology